← Human Trials & Peer-Reviewed Studies
Safety and efficacy of growth hormone (GH) during extended treatment of adult Japanese patients with GH deficiency (GHD).
Plain-language guide to PMID 18282776 (2008): double-blind randomized controlled trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).
Key Facts
- PMID
- 18282776
- Journal
- Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society
- Year
- 2008
- Study type
- Randomized Controlled Trial
- Authors
- Chihara K et al. (7 authors)
- DOI
- 10.1016/j.ghir.2007.12.001
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a randomized controlled trial.
Who Took Part
By PubMed's age tags, the people studied were teenagers, adults, middle-aged adults and older adults, both men and women.
How the Study Was Run
In design terms this was a randomized, double-blind, open-label, placebo-controlled and multicenter study.
Because people in this Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
As a double-blind Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study, the assignments were hidden from both participants and investigators until the end.
Nothing was hidden in this open-label Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study: the participants and staff both knew the treatment.
Some participants received a placebo instead of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), giving a reference point.
Body composition, serum lipids, serum IGF-I and IGF binding protein-3 (IGFBP-3) levels were measured throughout study.
Symptom and quality of life scores were also determined.
What Was Measured
Topics PubMed links to this paper include Algorithms, Growth Disorders, Hormone Replacement Therapy, Human Growth Hormone, Insulin-Like Growth Factor I and Japan.
What This Means in Plain Language
The paper is a randomized, double-blind and open-label study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).
The abstract goes on to report its results in about 12 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2008 (Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society), a journal based in Scotland.
More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.
Our Notes on the Compound
Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.